1 January 2024 false No description of principal activity Taxfiler 2024.6 13811971business:PrivateLimitedCompanyLtd2024-01-012024-12-31 138119712023-12-31 138119712024-01-012024-12-31 13811971business:AuditExempt-NoAccountantsReport2024-01-012024-12-31 13811971business:FilletedAccounts2024-01-012024-12-31 138119712024-12-31 13811971business:Director12024-01-012024-12-31 13811971business:RegisteredOffice2024-01-012024-12-31 138119712023-12-31 13811971core:WithinOneYear2024-12-31 13811971core:WithinOneYear2023-12-31 13811971core:ShareCapitalcore:PreviouslyStatedAmount2024-12-31 13811971core:ShareCapitalcore:PreviouslyStatedAmount2023-12-31 13811971core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-12-31 13811971core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-12-31 13811971core:PreviouslyStatedAmount2024-12-31 13811971core:PreviouslyStatedAmount2023-12-31 13811971business:SmallEntities2024-01-012024-12-31 13811971countries:EnglandWales2024-01-012024-12-31 13811971core:AdditionsToInvestments2024-12-31 13811971core:DisposalsRepaymentsInvestments2024-12-31 138119712023-01-012023-12-31 iso4217:GBP xbrli:pure
Company Registration No. 13811971 (England and Wales)
SANSURE BIOTECH UK LTD Unaudited accounts for the year ended 31 December 2024
SANSURE BIOTECH UK LTD Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
SANSURE BIOTECH UK LTD Company Information for the year ended 31 December 2024
Director
Yuxiang GONG
Company Number
13811971 (England and Wales)
Registered Office
1-3 Pemberton Row London EC4A 3BG
- 3 -
SANSURE BIOTECH UK LTD Statement of financial position as at 31 December 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Investments
4
5,428,872 
3,657,889 
Current assets
Debtors
5
63,921 
2,464,912 
Cash at bank and in hand
5,463 
6,959 
69,384 
2,471,871 
Creditors: amounts falling due within one year
6
(35,448)
(1,440)
Net current assets
33,936 
2,470,431 
Net assets
5,462,808 
6,128,320 
Capital and reserves
Called up share capital
9,369,624 
8,070,500 
Profit and loss account
(3,906,816)
(1,942,180)
Shareholders' funds
5,462,808 
6,128,320 
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 25 September 2025 and were signed on its behalf by
Yuxiang GONG Director Company Registration No. 13811971
- 4 -
SANSURE BIOTECH UK LTD Notes to the Accounts for the year ended 31 December 2024
1
Statutory information
SANSURE BIOTECH UK LTD is a private company, limited by shares, registered in England and Wales, registration number 13811971. The registered office is 1-3 Pemberton Row, London, EC4A 3BG.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Investments
Investments in shares are included at fair value if shares are publicly traded or their fair value can otherwise be measured reliably, otherwise investment in shares shall be measured at cost less impairment.
4
Investments
Subsidiary undertakings 
Other investments 
Total 
£ 
£ 
£ 
Valuation at 1 January 2024
1 
3,657,888 
3,657,889 
Additions
5,428,871 
- 
5,428,871 
Disposals
- 
(3,657,888)
(3,657,888)
Valuation at 31 December 2024
5,428,872 
- 
5,428,872 
5
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
Amounts due from group undertakings etc.
63,921 
2,464,912 
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Amounts owed to group undertakings and other participating interests
32,108 
- 
Taxes and social security
1,900 
- 
Accruals
1,440 
1,440 
35,448 
1,440 
- 5 -
SANSURE BIOTECH UK LTD Notes to the Accounts for the year ended 31 December 2024
7
Average number of employees
During the year the average number of employees was 0 (2023: 0).
- 6 -